Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASM-003
- Development stage
- Unknown
- Lead developer
- Guangzhou Aisima Bio-pharmaceutical Technology
- Modality
- Small Molecules
01
Overview
ASM-003 is a preclinical-stage small molecule therapeutic candidate being developed by Guangzhou Aisima Bio-pharmaceutical Technology (also known as ExcelMab). While Guangzhou Aisima Bio-pharmaceutical Technology is primarily recognized for its proprietary ExMab® platform and the development of multi-specific and bispecific antibody therapies for oncology and autoimmune diseases, ASM-003 represents a small molecule asset within its broader pipeline. Detailed information regarding its specific biological target, mechanism of action, and primary therapeutic indications remains undisclosed.
Beyond the preview
Go deeper on ASM-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASM-003.